{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:40:41Z","timestamp":1793338841306,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40265-025-02156-2","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:37:36Z","timestamp":1740224256000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"2156_CR1","unstructured":"Hahn BH. Systemic lupus erythematosus. In: Jameson JR, et al (eds) Harrison\u2019s principles of internal medicine, 21th edition. Columbus: McGraw-Hill; 2022. p. 2736\u201351."},{"key":"2156_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/1756-185X.13817","volume":"23","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020;23:465.","journal-title":"Int J Rheum Dis"},{"key":"2156_CR3","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European League against rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2156_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15\u201329.","journal-title":"Ann Rheum Dis"},{"key":"2156_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1152\/physrev.00011.2015","volume":"96","author":"K Hartmann","year":"2016","unstructured":"Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease and steroid therapy. Physiol Rev. 2016;96:409\u201347.","journal-title":"Physiol Rev"},{"issue":"5","key":"2156_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2215\/CJN.12991117","volume":"13","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Locatelli F. Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls. Clin J Am Soc Nephrol. 2018;13(5):815\u201322.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2156_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16:437\u201347.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2156_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary osteoporosis. Endocr Rev. 2022;43(2):240\u2013313.","journal-title":"Endocr Rev"},{"key":"2156_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/17446651.2020.1772051","volume":"15","author":"I Chiodini","year":"2020","unstructured":"Chiodini I, Falchetti A, Merlotti D, et al. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. Expert Rev Endocrinol Metab. 2020;15:283\u201398.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2156_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00774-024-01502-w","volume":"42","author":"Y Tanaka","year":"2024","unstructured":"Tanaka Y, Soen S, Hirata S, et al. The 2023 guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2024;42:143\u201354.","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"2156_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1046\/j.1365-2796.2003.01219.x","volume":"254","author":"P Vestergaard","year":"2003","unstructured":"Vestergaard P, Olsen ML, Paaske Johnsen S, Rejnmark L, S\u00f8rensen HT, Mosekilde L. Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med. 2003;254(5):486\u201393.","journal-title":"J Intern Med"},{"key":"2156_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00198-024-07023-6","volume":"35","author":"M Iki","year":"2024","unstructured":"Iki M, Fujimori K, Nakatoh S, et al. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int. 2024;35:805\u201318.","journal-title":"Osteoporos Int"},{"issue":"10","key":"2156_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/1756-185X.14856","volume":"26","author":"H Hanaoka","year":"2023","unstructured":"Hanaoka H, Kikuchi J, Hiramoto K, et al. Sarcopenia in patients with rheumatic musculoskeletal diseases. Int J Rheum Dis. 2023;26(10):2007\u201313.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2156_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/RHU.0000000000001980","volume":"30","author":"K Tam","year":"2024","unstructured":"Tam K, Wong-Pack M, Liu T, et al. Risk factors and clinical outcomes associated with sarcopenia in rheumatoid arthritis: a systematic review and meta-analysis. J Clin Rheumatol. 2024;30(1):18\u201325.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2156_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000590","volume":"8","author":"MF Ugarte-Gil","year":"2021","unstructured":"Ugarte-Gil MF, Mak A, Leong J, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021;8(1): e000590.","journal-title":"Lupus Sci Med."},{"issue":"9","key":"2156_CR16","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/rheumatology\/kez584","volume":"59","author":"M Piga","year":"2020","unstructured":"Piga M, Floris A, Sebastiani GD, et al. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology (Oxford). 2020;59(9):2272\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"2156_CR17","unstructured":"Wallace B, Gao Y, Kim H, et al. Time-dependent evaluation of weighted cumulative glucocorticoid exposure and major adverse cardiovascular events in a cohort of veterans with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2023;75(suppl 9). https:\/\/acrabstracts.org\/abstract\/time-dependent-evaluation-of-weightedcumulative-glucocorticoid-exposure-and-major-adverse-cardiovascular-events-in-a-cohort-of-veterans-withrheumatoid-arthritis\/. Accessed 12 Feb 2025."},{"issue":"7","key":"2156_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/rheumatology\/keae041","volume":"63","author":"G Bertsias","year":"2024","unstructured":"Bertsias G, Askanase A, Doria A, Saxena A, Vital EM. A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus. Rheumatology (Oxford). 2024;63(7):1837\u201349.","journal-title":"Rheumatology (Oxford)"},{"key":"2156_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1109\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"2156_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recomrmendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"2156_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345.","journal-title":"Ann Rheum Dis"},{"key":"2156_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr2.11267","volume":"3","author":"K Tselios","year":"2021","unstructured":"Tselios K, Gladman DD, Su J, et al. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus. ACR Open Rheumatol. 2021;3:550\u20137.","journal-title":"ACR Open Rheumatol"},{"key":"2156_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/09612033211002269","volume":"30","author":"S Fasano","year":"2021","unstructured":"Fasano S, Coscia MA, Pierro L, et al. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? results from a single inception cohort study. Lupus. 2021;30:991\u20137.","journal-title":"Lupus"},{"issue":"1","key":"2156_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena A, Ginzler EM, Gibson K, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024;76(1):59\u201367.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2156_CR25","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","volume":"60","author":"L Ji","year":"2021","unstructured":"Ji L, Xie W, Zhang Z. Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual. Rheumatology (Oxford). 2021;60(12):5517\u201326.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2156_CR26","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/09612033211002269","volume":"30","author":"S Fasano","year":"2021","unstructured":"Fasano S, Coscia MA, Pierro L, Ciccia F. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study. Lupus. 2021;30(6):991\u20137.","journal-title":"Lupus"},{"issue":"10","key":"2156_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102898","volume":"20","author":"G Ruiz-Irastorza","year":"2021","unstructured":"Ruiz-Irastorza G, Due\u00f1a-Bartolome L, Dunder S, et al. Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. Autoimmun Rev. 2021;20(10): 102898.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2156_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/acr.24592","volume":"74","author":"K Tselios","year":"2022","unstructured":"Tselios K, Gladman DD, Al-Sheikh H, Su J, Urowitz MB. Medium versus high initial prednisone dose for remission induction in lupus nephritis: a propensity score-matched analysis. Arthritis Care Res (Hoboken). 2022;74(9):1451\u20138.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2156_CR29","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1\u201369.","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"2156_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"S Navarra","year":"2011","unstructured":"Navarra S, Guzm\u00e1n RM, Gallacher AE, BLISS-52 Study Group, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721\u201331.","journal-title":"Lancet"},{"key":"2156_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae S, Bass D, Chu M, Egginton S, Gordon D, Roth D, Zheng J, Tanaka Y. A pivotal Phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355\u201363.","journal-title":"Ann Rheum Dis"},{"key":"2156_CR32","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1093\/rheumatology\/keab953","volume":"61","author":"Y Miyazaki","year":"2022","unstructured":"Miyazaki Y, Nakayamada S, Sonomoto K, et al. Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology. 2022;61:3614\u201326.","journal-title":"Rheumatology"},{"key":"2156_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"2156_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","volume":"13","author":"G Ruiz-Irastorza","year":"2014","unstructured":"Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014;13(2):206\u201314.","journal-title":"Autoimmun Rev"},{"issue":"10289","key":"2156_CR35","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070\u201380.","journal-title":"Lancet"},{"issue":"2","key":"2156_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ajkd.2023.02.003","volume":"82","author":"LH Beck Jr","year":"2023","unstructured":"Beck LH Jr, Ayoub I, Caster D, et al. KDOQI US Commentary on the 2021 KDIGO clinical practice guideline for the management of glomerular diseases. Am J Kidney Dis. 2023;82(2):121\u201375.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2156_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001068","volume":"11","author":"G Figueroa-Parra","year":"2024","unstructured":"Figueroa-Parra G, Putman MS, Crowson CS, Duarte-Garc\u00eda A. Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Sci Med. 2024;11(1): e001068.","journal-title":"Lupus Sci Med."},{"key":"2156_CR38","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1191\/0961203303lu450xx","volume":"12","author":"K Saito","year":"2003","unstructured":"Saito K, Nawata M, Nakayamada S, et al. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus. 2003;12:798\u2013800.","journal-title":"Lupus"},{"issue":"10","key":"2156_CR39","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1136\/annrheumdis-2012-201317","volume":"71","author":"S Iwata","year":"2012","unstructured":"Iwata S, Saito K, Tokunaga M, Tanaka Y. B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis. 2012;71(10):1749\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2156_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/1756-185X.12534","volume":"18","author":"S Nakayamada","year":"2015","unstructured":"Nakayamada S, Iwata S, Tanaka Y. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. Int J Rheum Dis. 2015;18(2):208\u201318.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2156_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222\u201333.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2156_CR42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215\u201326.","journal-title":"Arthritis Rheum"},{"key":"2156_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/mr\/roac007","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Nakayamada S, Yamaoka K, Ohmura K, Yasuda S. Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan. Mod Rheumatol. 2023;33:145\u201353.","journal-title":"Mod Rheumatol"},{"key":"2156_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"2156_CR45","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496\u2013506.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2156_CR46","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"7","key":"2156_CR47","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:29:47Z","timestamp":1743478187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2156"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02156-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There was no funding for preparing the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"YT has received speaking fees and\/or honoraria from Abbvie, Eisai, Chugai, Eli-Lilly, Behringer-Ingelheim, GlaxoSmithKline, Taisho, AstraZeneca, Daiichi-Sankyo, Gilead, Pfizer, UCB, Asahi-kasei, Astellas, received research grants from Behringer-Ingelheim, Taisho, Chugai. However, they are not relevant to preparation of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Substantial contributions to review conception, interpretation of reviewed literature, drafting the article, revising it critically for important intellectual content, and final approval of the version of the article to be published: YT.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}